Skip to main content
. 2014 Jan 17;306(6):L476–L486. doi: 10.1152/ajplung.00253.2013

Fig. 2.

Fig. 2.

Pharmacology of KCNQ currents in rat ASMCs. Representative time courses of retigabine [A; 10 μM, cell capacitance (C) = 23.6 pF]-, zinc pyrithione (ZnPyr; C; 100 nM, C = 14.3 pF)-, and 2,5-dimethylcelecoxib (DMC; E; 10 μM, C = 20.2 pF)-induced enhancement of endogenous KCNQ currents recorded in ASMCs at −20 mV holding voltage. A break in the recording (10 min) is indicated by 2 vertical gray lines. B, D, and F: current-voltage (I–V) relationships of KCNQ currents recorded in ASMCs before (control, filled circles); during treatment with 10 μM retigabine (B; open circles, n = 3), 100 nM ZnPyr (D; open circles, n = 4), and 10 μM DMC (F; open circles, n = 7); and after 5-min treatment with the KCNQ channel blocker XE991 in the presence of each activator (10 μM, filled triangles). *Significant difference from control (one-way repeated-measures ANOVA, P < 0.05).